Neumora Posts $34.4M Q3 Loss, $85.7M Cash, Skips Runway Guidance
NMRA sits 33% above its 52-week low of $0.315 on light trading volume (0.3× avg).
Summary
Neumora ended Q3 with $85.7 million in cash and a $34.4 million net loss, down from $56.8 million a year ago as R&D spending fell to $22.6 million from $40.5 million, with a third-quarter loss per share of 18 cents. The company declined to give updated runway guidance and said it will need substantial additional funding, with the 10-Q flagging going-concern doubt. Pipeline updates: an IND was submitted for NMRA-215 in obesity, and the 30 mg BID NMRA-511 cohort showed no serious adverse events with dose-proportional exposure, making that program Phase 2 enabled. The cash burn versus a roughly $81 million market cap keeps dilution risk front and center, and the October 26 Nasdaq minimum-bid notice adds a listing overhang. No specific date was given for the next data readout.
At the time of this announcement, NMRA was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.6M. The 52-week trading range was $0.32 to $3.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.